Penumbra (PEN) Reports Q2 Earnings: What Key Metrics Have to Say

Core Insights - Penumbra reported revenue of $299.4 million for the quarter ended June 2024, reflecting a year-over-year increase of 14.5% [8] - The earnings per share (EPS) for the same quarter was $0.64, up from $0.43 in the previous year, indicating a strong performance [8] - The revenue surprise was +0.28% over the Zacks Consensus Estimate of $298.58 million, while the EPS surprise was +14.29% compared to the consensus estimate of $0.56 [2] Revenue Performance - The revenue from the Embolization and Access segment was reported at $81.22 million, exceeding the average estimate of $74.90 million by two analysts, representing an 8.7% increase year-over-year [4] - Revenue from the Thrombectomy segment was $95.90 million, slightly below the average estimate of $98.62 million based on four analysts [5] - Overall revenue performance showed a year-over-year change of +16.8% compared to the two-analyst average estimate of $223.85 million, which was reported at $218.18 million [3] Market Performance - Over the past month, Penumbra shares have returned +0.7%, outperforming the Zacks S&P 500 composite's +0.1% change [7] - The stock currently holds a Zacks Rank 2 (Buy), suggesting potential for outperformance in the near term [7]